本周关注点 公司公告汇总 宁波德业科技股份有限公司将于2025年5月21日召开2024年年度股东大会，会议地点为宁波市北仑区甬 江南路26号研发楼7楼。会议将审议多项议案，包括2024年度董事会工作报告、监事会工作报告、独立 董事述职报告、财务决算报告、年度报告及其摘要、利润分配及资本公积金转增股本方案、使用自有资 金进行现金管理、公司及子公司向银行申请综合授信额度及对外担保额度、开展外汇套期保值业务、董 事薪酬方案、监事薪酬方案等。公司及子公司拟使用最高不超过80亿元的自有资金进行现金管理，并向 银行申请不超过200亿人民币的综合授信额度。此外，公司计划开展不超过15亿美元的外汇套期保值业 务。 业绩披露要点 截至2025年5月9日收盘，德业股份（605117）报收于89.5元，较上周的86.2元上涨3.83%。本周，德业 股份5月8日盘中最高价报90.28元。5月6日盘中最低价报86.1元。德业股份当前最新总市值578.14亿元， 在光伏设备板块市值排名4/62，在两市A股市值排名234/5145。 2024年公司实现营业收入112.06亿元，同比增长49.82%，归属于母公司股东的净利润29.60亿元， ...

Core Points - The company is preparing for the 2024 Annual General Meeting (AGM) to discuss various proposals including financial reports, profit distribution, and governance changes [2][3][4] Proposal Summaries - Proposal 1: The company will present the 2024 Board of Directors' Work Report for shareholder approval [3] - Proposal 2: The company will present the 2024 Supervisory Board's Work Report for shareholder approval [3] - Proposal 3: The company will present the 2024 Annual Report and its summary for shareholder approval [3] - Proposal 4: The company will present the 2024 Financial Settlement Report for shareholder approval [3] - Proposal 5: The company proposes a profit distribution plan, distributing cash dividends of RMB 4.50 per 10 shares, totaling RMB 120 million, which is 59.48% of the net profit [3] - Proposal 6: The company will confirm the salaries and allowances for non-independent directors and senior management for 2024, with the chairman receiving RMB 145.41 million [3] - Proposal 7: The company will confirm the salaries and allowances for independent directors for 2024, with the highest being RMB 6.72 million [3] - Proposal 8: The company proposes to reappoint Tianzhi International Accounting Firm for the 2025 financial report and internal control audit, with fees totaling RMB 1 million [4] - Proposal 9: The company plans to use idle funds for cash management to enhance investment returns [4] - Proposal 10: The company will review the execution of daily related transactions for 2024 and the expected amount for 2025 [5] - Proposal 11: The company plans to conduct foreign exchange hedging with a total amount not exceeding RMB 2 billion [6] - Proposal 12: The company plans to provide guarantees for its subsidiary, with amounts not exceeding RMB 2 billion for one subsidiary and RMB 3 billion for another [7] - Proposal 13: The company will sign a financial service agreement with Supply and Marketing Group Financial Co., Ltd. to improve liquidity [8] - Proposal 14: The company plans to change its business scope and amend its articles of association [9] - Proposal 15: The company will revise the rules of procedure for board meetings and shareholder meetings [10] - Proposal 16: The company will revise the independent director working rules and other governance systems [12] - Proposal 17: The company proposes to abolish the supervisory board and its rules [13] Financial Performance - The company reported a revenue of RMB 1,059,581.84 million for the year, an increase of 1.30% compared to the previous year [14] - The raw material prices in the agricultural chemical industry have decreased, with the raw material price index dropping by 9.07% year-on-year [14]

江苏常州 二〇二五年五月二十日 江苏武进不锈股份有限公司（603878） 2024 年年度股东大会会议资料 《关于公司非独立董事（除董事长、副董事长外）薪酬的议案》- 30 - 江苏武进不锈股份有限公司 会议资料 公司登记在册的本公司股东。因故不能亲自出席会议的股东，可以委托授权代理 人参加会议，代理人可以不是本公司股东。 议案八： 江苏武进不锈股份有限公司（603878） 2024 年年度股东大会会议资料 -2- 江苏武进不锈股份有限公司 一、会议时间 ①网络投票系统：上海证券交易所股东大会网络投票系统。 ②网络投票起止时间：自 2025 年 5 月 20 日至 2025 年 5 月 20 日。 ③采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为 股东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 二、现场会议地点：江苏省常州市天宁区郑陆镇武澄西路 1 号公司二楼职工 培训室。 三、出席现场会议对象： 四、见证律师：江苏正气浩然律师事务所梁永伟、邹逸韬。 五、现场会议议 ...

Financial Data and Key Metrics Changes - Aflac reported net earnings per diluted share of $0.05, significantly impacted by net investment losses compared to net investment gains in Q1 2024 [5] - Adjusted earnings per diluted share remained unchanged at $1.66 year over year [5][13] - Adjusted return on equity (ROE) was 12.7% excluding foreign currency remeasurement, indicating a solid performance [13] - Adjusted book value per share, excluding foreign currency remeasurement, increased by 2.2% [13] Business Line Data and Key Metrics Changes - Aflac Japan experienced a 12.6% year-over-year sales increase, driven by significant contributions from Sumitas and a 6.3% increase in cancer insurance sales [5][6] - Aflac US saw a 3.5% year-over-year increase in sales, with strong performance in group life, disability, and network dental [8] - Net earned premiums in Aflac Japan declined by 5%, while underlying earned premiums adjusted for deferred profit liability and reinsurance declined by 1.4% [14] - In the US, net earned premiums increased by 1.8%, with persistency rising by 60 basis points year over year to 79.3% [17] Market Data and Key Metrics Changes - Aflac Japan's total benefit ratio was 65.8%, down 120 basis points year over year, while the US total benefit ratio was 47.7%, up 120 basis points year over year [15][18] - Persistency in Japan remained solid at 93.8%, up 40 basis points year over year [16] - The expense ratio in Japan increased to 19.6%, primarily due to higher technology expenses, while the US expense ratio decreased to 37.6% [16][19] Company Strategy and Development Direction - Aflac aims to appeal to younger customers through products like Sumitas, which has been successful in reaching this demographic [6] - The company is focused on maintaining strong premium persistency and driving profitable growth through stronger underwriting discipline [8] - Aflac continues to leverage its strong capital and cash flows while maintaining prudent liquidity and capital management [10] - The company is committed to reinforcing its leading position in the life insurance markets of Japan and the US [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand for Aflac's products, emphasizing the importance of being a partner in health for policyholders [9] - The company is optimistic about the growth potential in both Japan and the US, with plans to continue capital deployment and maintain a strong dividend track record [11][12] - Management acknowledged the challenges posed by macroeconomic factors but remains committed to long-term capital management strategies [36] Other Important Information - Aflac repurchased $900 million worth of its own stock and paid $317 million in dividends during Q1 2025 [23] - The company ended the quarter with strong capital ratios, including an estimated regulatory ESR above 250% [24] - Aflac Japan's cancer insurance sales are expected to grow, supported by the launch of a new cancer product in March 2025 [52] Q&A Session Summary Question: Why did the ESR ratio decline in Q1? - Management explained that the decline was due to the strengthening yen, partially offset by higher Japan interest rates and significant dividends flowing from Aflac Japan to Aflac Inc [32] Question: How should capital planning be approached given recent macro changes? - Management stated that capital management is designed with a long-term view, and they do not plan to change their approach significantly despite recent volatility [36] Question: What are the expectations for the new cancer product sales? - Management expressed confidence in the new cancer product's growth, anticipating continued sales increases throughout 2025 [52] Question: How is the competitive landscape for medical insurance in Japan? - Management acknowledged increased competition but emphasized Aflac's pioneering position and unique services that provide a competitive advantage [56] Question: How does the company view the impact of the yen on its operations? - Management noted that while a strengthening yen introduces volatility, it also leads to higher future dividends in dollar terms from Aflac Japan, which offsets some negative impacts [95]

登录新浪财经APP 搜索【信披】查看更多考评等级 本年度公司现金分红总额53,812,057.90元；本年度以现金为对价，采用集中竞价方式已实施的股份回购 金额75,864,030.95元，现金分红和回购金额合计129,676,088.85元，占本年度归属于上市公司股东净利润 的比例136.39%。其中，以现金为对价，采用要约方式、集中竞价方式回购股份并注销的回购（以下简 称回购并注销）金额0元，现金分红和回购并注销金额合计53,812,057.90元，占本年度归属于上市公司 股东净利润的比例56.60%。 如在本公告披露之日起至实施权益分派股权登记日期间，因可转债转股/回购股份/股权激励授予股份回 购注销/重大资产重组股份回购注销等致使公司总股本发生变动的，公司拟维持每股分配比例不变，相 应调整分配总额。如后续总股本发生变化，将另行公告具体调整情况。 本次利润分配方案尚需提交股东大会审议。 （二）是否可能触及其他风险警示情形 公司上市已满三个完整会计年度，本年度净利润为正值且母公司报表年度末未分配利润为正值，公司不 触及其他风险警示情形，具体如下： ■ 二、公司履行的决策程序 （一）董事会会议的召开、审议和 ...

Core Viewpoint - The company has approved a proposal to engage in foreign exchange hedging activities to mitigate risks associated with currency fluctuations as its overseas business grows [1][2]. Group 1: Foreign Exchange Hedging Activities - The company plans to conduct foreign exchange hedging activities, including but not limited to forward foreign exchange contracts, foreign exchange swaps, foreign exchange options, and other foreign exchange derivatives, with a maximum contract amount of up to 10 million USD or equivalent foreign currency [1]. - The authorization for these activities is valid for 12 months from the date of the board's approval, allowing for the funds to be used in a rolling manner within the specified limit [1]. - The board has authorized the general manager to approve daily foreign exchange hedging plans and sign related contracts, with the finance department responsible for the operation and management of these activities [1]. Group 2: Risk Management and Internal Controls - The foreign exchange hedging activities will primarily involve standard forward foreign exchange products and foreign exchange swaps, limited to the main settlement currencies used in the company's operations [2]. - The maximum delivery period for these hedging activities is generally not to exceed 12 months, and the funding for these activities will come from the company's own funds [2]. - The company has implemented strict internal review and risk control measures, including managing accounts receivable actively to prevent delays in delivery for forward foreign exchange contracts [2]. Group 3: Board Approval - The proposal was approved by the company's third board meeting with 7 votes in favor, 0 against, and 0 abstentions, and does not require submission to the shareholders' meeting for further approval [2]. - Relevant documents include the resolution of the third board meeting and the decision from the first special meeting of independent directors in 2025 [2].

Core Viewpoint - The company reported a decline in revenue and net profit for the year 2024, primarily due to falling prices of pesticide products, despite an increase in production and sales volume [18]. Group 1: Company Overview - The company, Haier Pharmaceutical Group Co., Ltd., is engaged in the research, production, and sales of pesticide formulations, intermediates, and raw materials, with a focus on insecticides and fungicides [4][15]. - The pesticide industry is characterized by relatively inelastic demand, playing a crucial role in agricultural production and food security [2][3]. Group 2: Financial Performance - The company achieved operating revenue of CNY 3.91 billion in 2024, a decrease of 11.16% from CNY 4.40 billion in 2023 [18]. - The net profit attributable to shareholders was CNY 181.37 million, down 61.67% from CNY 473.20 million in the previous year [18]. - The net cash flow from operating activities was CNY 285.55 million, a significant decrease of 70.11% compared to CNY 955.35 million in 2023 [18]. Group 3: Market Dynamics - The global demand for pesticides is expected to grow due to increasing food security needs and agricultural efficiency [2]. - China's pesticide production capacity is shifting towards countries like China and India, driven by the expiration of patents and restructuring by multinational agrochemical giants [2][3]. Group 4: Product Development - The company has been diversifying its pesticide offerings, with several new products entering trial production in recent years, including various insecticides and fungicides [4][5]. - The company is focusing on high-efficiency, low-toxicity pesticides to meet the growing market demand [2][4]. Group 5: Industry Trends - The pesticide industry is experiencing a shift towards biopesticides and environmentally friendly products, with increasing market share for biological and chemical pesticides [7]. - The market for generic pesticides is expected to expand as patents expire, providing opportunities for companies with strong R&D capabilities [2][3].

Group 1 - The company approved the proposal to reappoint Lixin as the auditor for the 2025 financial report and internal control audit [1][2] - The decision was made unanimously by the board with 8 votes in favor and no opposition [2] - The reappointment is subject to approval at the 2024 annual general meeting [2][6] Group 2 - The company announced a profit distribution plan for 2024, proposing a cash dividend of 2.0 yuan per 10 shares, totaling approximately 28.37 million yuan [4][5] - The net profit attributable to shareholders for 2024 is reported at approximately 90.18 million yuan, with distributable profits at approximately 280.52 million yuan [3][4] - The proposed cash dividend represents 42.56% of the net profit attributable to the parent company [5] Group 3 - The company plans to conduct foreign exchange hedging activities to mitigate risks associated with currency fluctuations, with a maximum amount of 300 million yuan or equivalent in foreign currency [10][12] - The hedging activities will involve major currencies such as USD and EUR, using methods like forward contracts and options [15][19] - The board approved the hedging proposal without requiring shareholder approval [20] Group 4 - The company provided a guarantee of 70 million yuan for its wholly-owned subsidiary, Wenzhou Weigang International Trade Co., Ltd., to support its bank credit needs [30][31] - The guarantee is valid for 12 months and can be reused within the approved limit [30][31] - The total amount of guarantees provided by the company is 70 million yuan, which accounts for 6.11% of the latest audited net assets [34] Group 5 - The company announced adjustments to the construction content of its fundraising project for a new production line, maintaining the total investment amount [35][45] - The project aims to enhance resource efficiency and ensure smooth implementation, with expected annual output value of approximately 79.24 million yuan [41][45] - The adjustments were approved by both the board and the supervisory committee and will be submitted for shareholder approval [46][48]

■ 除上述条款修订及条款序号同步更新外，《公司章程》其他内容不变。 浙能电力《股东会议事规则》修订对比表 ■ 除上述条款修订及条款序号同步更新外，《股东会议事规则》其他内容不变。 浙能电力《董事会议事规则》修订对比表 ■ 证券代码：600023 证券简称：浙能电力 公告编号：2025-008 浙江浙能电力股份有限公司 第五届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 （一）浙江浙能电力股份有限公司（以下简称"公司"）第五届监事会第四次会议的召开符合《公司 法》、《公司章程》及有关法律、法规、规范性文件的规定，会议合法有效。 （二）本次会议通知于2025年4月17日以书面形式发出。 （三）本次会议于2025年4月27日在公司本部以现场结合通讯表决方式召开。 2.审议通过《2024年度财务决算报告》 表决情况：3票同意，0票反对，0票弃权 本议案需提交公司股东大会审议。 3.审议通过《2025年度财务预算报告》 表决情况：3票同意，0票反对，0票弃权 （四）会议应出席监事3人， ...

Group 1 - The company raised a total of RMB 1,026.87 million through a non-public offering of 99.89 million shares at a price of RMB 10.28 per share, with net proceeds amounting to RMB 1,014.40 million after deducting fees [2][3] - The company has established a dedicated account for the management of raised funds, signing tripartite and quadripartite supervision agreements with relevant banks and sponsors to ensure proper fund usage [3][4] - As of December 31, 2024, the company maintained one dedicated account for the raised funds [4] Group 2 - The company reported that the actual use of raised funds has been delayed for several projects, including the "Pharmaceutical Comprehensive R&D Center" and "Environmental Facility Renovation Project," due to strategic adjustments and external factors [5][6] - The "Pharmaceutical Comprehensive R&D Center" project was transferred to a subsidiary, and the implementation location was changed, leading to delays in investment progress [5][6] - The company stated that the benefits of certain projects cannot be individually accounted for, as their effectiveness is reflected indirectly through product quality improvements [7][10] Group 3 - The company reported a net loss of RMB 330.27 million for the year 2024, with total revenue of RMB 1,938.47 million [24][28] - The company proposed not to distribute cash dividends for 2024 due to the reported losses, aligning with its dividend policy [28] - The company has established a robust internal control system, ensuring compliance with relevant laws and regulations [31]